Sorry, I fail to see the logic of the SP.
If ATL1102 is as good as JG and the team claims, then buyer interest should be there to buy not sell out.
Whilst I accept the drug is still in development the current results and lack of competition should surely mean investors are lining up,
or am I missing something here?
Just a dumbass retail investor commenting
regards
Bluesky
PER - Megathread, page-231
-
- There are more pages in this discussion • 136 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
